Principal Investigator
Division of Hematology & Oncology
Division of General Internal Medicine
Division of Rheumatology
Division of Others-
Division of Hematology & Oncology
更新時間：2023-09-19
- Principal Investigator
- Clinical Trial Experience (year) 23 years 9 個月
Highlights
2. Country principal Investigator: Tisagenlecleucel versus standard of care in adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: A randomized, open label, phase III trial (BELINDA). (Clinicaltrials.gov Identifier: NCT03570892)
3. Country principal Investigator: Long Term Follow-Up of Patients Exposed to Lentiviral- Based CAR T-Cell Therapy. (Clinicaltrials.gov Identifier: NCT02445222)
4. Country Sub-Investigator: Infusion of CD19-Specific Chimeric Antigen Receptor T Cells Produced by Rapid Personalized Manufacture for Patients with Advanced Lymphoid Malignancies. (Clinicaltrials.gov Identifier: NCT 04844086)
5. Country Sub-Investigator: A Phase 1/2 multicenter, open-label, single-arm study to evaluate the safety and efficacy of CD19-targeted chimeric antigen receptor T-cell (CD19 CAR-T) therapy in patients with relapsed or refractory B-cell lymphoma. (NTUH IRB Number: 202103027DSC)
Study Area
- Hematological diseases
Professional Experiences
Clinical Assistant Professor
Department of Internal Medicine
Attending Physician
Division of Hematology, Department of Internal Medicine
Education
School of Medicine, College of Medicine
M.D.
Clinical Trials List
2016
Total 249
-
I 31
-
I/II 21
-
II 38
-
II/III 5
-
III 140
-
IV 5
-
Others 9
Number of Studies by Scale
13件
Taiwan Multiple Center
Taiwan Single Center
3Cases
Taiwan Multiple Center
13Cases
Multi-Regional Multi-Center
252Cases
